Kazia Therapeutics (NASDAQ:KZIA) Now Covered by Maxim Group

Maxim Group started coverage on shares of Kazia Therapeutics (NASDAQ:KZIA) in a report published on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.

Kazia Therapeutics Price Performance

Shares of NASDAQ KZIA opened at $1.50 on Thursday. Kazia Therapeutics has a 52-week low of $1.31 and a 52-week high of $15.80. The business’s 50 day moving average is $2.48 and its two-hundred day moving average is $3.73.

Hedge Funds Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics as of its most recent filing with the Securities & Exchange Commission. 30.89% of the stock is owned by institutional investors and hedge funds.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.